Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.
Market Data
Essential tool: analyze, trade, manage, decide.
What’s Your Call?
Collective community sentiment on Checkpoint Trends Ltd
Your Vote -
Buy
50.00%
Hold
0.00%
Sell
50.00%
50.00%
2 users have voted
Option Chain
Analyzes market sentiment, predicts Checkpoint Trends Ltd' movement.
NO_RECORD_FOUND
News
Media spotlight triggers stock stock attention, sentiment.
-
Checkpoint Trends - Board Meeting Intimation for Intimation Of Board Meeting For Approval Of Financial Results
-
Checkpoint Trends - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
-
Checkpoint Trends - Board Meeting Outcome for Outcome Of Board Meeting
-
Checkpoint Trends - Board Meeting Intimation for Intimation Of Board Meeting
-
Checkpoint Trends - Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
-
Checkpoint Trends - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
-
Checkpoint Trends - Newspaper Announcements
-
Checkpoint Trends - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
-
Checkpoint Trends - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
-
Checkpoint Trends - Board Meeting Outcome for Outcome Of Board Meeting
-
Checkpoint Trends has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2025
-
Checkpoint Trends - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
-
Checkpoint Trends - Board Meeting Intimation for Intimation Of Board Meeting
-
Checkpoint Trends - Board Meeting Outcome for Outcome Of Board Meeting
-
Checkpoint Trends - Board Meeting Intimation for Appointment Of Non- Executive Independent Directors
-
Checkpoint Trends - Announcement under Regulation 30 (LODR)-Resignation of Director
-
Checkpoint Trends - Board Meeting Outcome for Outcome Of Board Meeting
-
Checkpoint Trends - Board Meeting Intimation for Board Meeting Intimation For Appointment Of Whole-Time Directors And Non-Exe
Key fundamentals
Evaluate the intrinsic value of Checkpoint Trends Ltd stock
| Name | March-24 | March-23 | March-22 | March-21 | March-20 |
|---|---|---|---|---|---|
| Assets | 0.5327 | 0.6499 | 0.581 | 0.6176 | 0.612 |
| Liabilities | 0.5327 | 0.6499 | 0.581 | 0.6176 | 0.612 |
| Equity | 5.4683 | 5.4683 | 5.4683 | 5.4683 | 5.4683 |
| Gross Profit | 0.0287 | -0.0793 | -0.0214 | 0.0099 | 0.0178 |
| Net Profit | 0.0302 | -0.0785 | -0.0365 | 0.0056 | 0.0315 |
| Cash From Operating Activities | -0.0163 | 0.0137 | -0.4999 | 0.1519 | 0.1161 |
| NPM(%) | 2.67 | -6.77 | -1.81 | 1.15 | 3.19 |
| Revenue | 1.13 | 1.1601 | 2.0111 | 0.485 | 0.9876 |
| Expenses | 1.1012 | 1.2394 | 2.0325 | 0.475 | 0.9697 |
| ROE(%) | 5.67 | -14.74 | -6.85 | 1.05 | 5.92 |
Corporate Action
| XD-Date | Dividend-Amount | Dividend-% | Dividend Yield(%GE) | Price on that day |
|---|
Peers
Other companies within the same industry or sector that are comparable to Checkpoint Trends Ltd
| Company | Price | Price (% change) | pe(x) | EV/EBITDA(x) | ROE(%) | ROCE(%) |
|---|---|---|---|---|---|---|
| Albert David Ltd | 810.05 | -1.12 | 26.88 | 12.21 | 301.39 | 0.62 |
| Lotus Eye Hospital and Institute Ltd | 74.39 | 0.39 | 308.58 | 44.48 | 14.01 | 0.68 |
| Bharat Immunological and Biologicals Corporation Ltd | 25.66 | -5.45 | 0.00 | 92.36 | -39.50 | 0.00 |
| Astec Lifesciences Ltd | 698.00 | -1.87 | 0.00 | 41.94 | -687.11 | 0.00 |
Company Info
Rubra Medicaments Limited was incorporated on 27th September, 1991 as a Private Limited Company under the Companies Act, 1956, in the name of Rubra Medicaments Private Limited. The Company was subsequently converted into a Public Limited Company and the name of the Company was changed to Rubra Medicaments Limited with effect from 2nd December, 1994. The Company's existing factory for manufacture of pharmaceutical formulations is located at Plot.No.109/3, IDA, Phase-II, Cherlapally, R.R.District (A.P) with an installed capacity as under: Tablets - 339.60 lacs nos. Capsules - 90.00 lacs nos. The Company has started operations from March' 1994 and presently manufactures antimalarial, antispasmodic, antianelgesic, antiasthamatic and antibiotics formulations, in tablets and capsule form. The Company also manufactures generic and calcium tablets. The Company now proposes to expand its existing capacity for tablets and capsules and also manufacture Anti Rheumatic Drug, Analgesic and Antipyritic drugs, Antipeptic ulcerant Drugs, Antianthraitic (Tropical Cream), Anti-infective (Skin Preparation), Nutrition supplement (Aur. Iron preparation) formulations. 2010 -Registered Office of the Company has been shifted From 109/3, IDA Phase II, Sector II, Lane 6, Cherlapally, Hyderabad - 500051 To 4-1-896, Shop No.32, Sri Rama Towers, Boggulkunta, Tilak Road, Hyderabad -500001. 2011 -Registered Office of the Company has been shifted From 4-1-896, Shop no: 32, Sri Rama Towers, Boggulkupta, Tilak Road, Hyderabad, Andhra Pradesh To 1-18-117/4, Police Lane, GunBazar Begumpet, Hyderabad, Andhra Pradesh - 500003. 2016 - The Company has shifted Registered office to Rubra Medicaments Limited 28, Level 1, am@10, MB Towers,H No. 8-2-624/A/1,Road No. 10, Banjara Hills,Hyderabad - 500034 Telangana, India 2023 -Company name has changed to Checkpoint Trends Ltd. from Rubra Medicaments Ltd..
Rubra Medicaments Limited was incorporated on 27th September, 1991 as a Private Limited Company under the Companies Act, 1956, in the name of Rubra Medicaments Private Limited. The Company was subsequently converted into a Public Limited Company and the name of the Company was changed to Rubra Medicaments Limited with effect from 2nd December, 1994. The Company's existing factory for manufacture of pharmaceutical formulations is located at Plot.No.109/3, IDA, Phase-II, Cherlapally, R.R.District (A.P) with an installed capacity as under: Tablets - 339.60 lacs nos. Capsules - 90.00 lacs nos. The Company has started operations from March' 1994 and presently manufactures antimalarial, antispasmodic, antianelgesic, antiasthamatic and antibiotics formulations, in tablets and capsule form. The Company also manufactures generic and calcium tablets. The Company now proposes to expand its existing capacity for tablets and capsules and also manufacture Anti Rheumatic Drug, Analgesic and Antipyritic drugs, Antipeptic ulcerant Drugs, Antianthraitic (Tropical Cream), Anti-infective (Skin Preparation), Nutrition supplement (Aur. Iron preparation) formulations. 2010 -Registered Office of the Company has been shifted From 109/3, IDA Phase II, Sector II, Lane 6, Cherlapally, Hyderabad - 500051 To 4-1-896, Shop No.32, Sri Rama Towers, Boggulkunta, Tilak Road, Hyderabad -500001. 2011 -Registered Office of the Company has been shifted From 4-1-896, Shop no: 32, Sri Rama Towers, Boggulkupta, Tilak Road, Hyderabad, Andhra Pradesh To 1-18-117/4, Police Lane, GunBazar Begumpet, Hyderabad, Andhra Pradesh - 500003. 2016 - The Company has shifted Registered office to Rubra Medicaments Limited 28, Level 1, am@10, MB Towers,H No. 8-2-624/A/1,Road No. 10, Banjara Hills,Hyderabad - 500034 Telangana, India 2023 -Company name has changed to Checkpoint Trends Ltd. from Rubra Medicaments Ltd..
Read More
Parent Organisation
Checkpoint Trends Ltd.
Founded
27/09/1991
Managing Director
Mr.Sunil Khandalwal
NSE Symbol
FAQ
The current price of Checkpoint Trends Ltd is
The 52-week high for Checkpoint Trends Ltd is
The market capitalization of Checkpoint Trends Ltd is currently This value can fluctuate based on stock price movements and changes in the number of shares outstanding.
To buy Checkpoint Trends Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.
To invest in Checkpoint Trends Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Checkpoint Trends Ltd shares.
The CEO of Checkpoint Trends Ltd is Mr.Sunil Khandalwal, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.
